Fuller H B Co (FUL) · Oct 9, 2026 · New debt
$850M notes priced — 7.625% coupon; $450M redemption if AMS deal fails
H.B. Fuller priced $850 million of debt for its AMS acquisition, securing funding but adding expensive long-term borrowing and refinancing pressure.
H.B. Fuller is shifting its portfolio toward higher-growth medical adhesives through its pending acquisition of Advanced Medical Solutions, a deal already agreed in June and approved by AMS shareholders in August. The transaction is intended to add medical technologies, regulatory capabilities and commercial reach, with roughly $55 million of expected run-rate synergies by 2031.
The financing removes a key execution hurdle, but it is expensive capital. H.B. Fuller priced $850 million of senior unsecured notes at a 7.625% coupon, implying roughly $65 million of annual interest before any refinancing effects. The proceeds will fund the AMS purchase, repay credit-agreement borrowings and redeem the company’s cheaper 4.000% notes due February 2027. 〔0〕
This is partly confirmation rather than a fresh strategic surprise. The AMS acquisition and its bridge financing were already disclosed, so the new information is the permanent funding mix and its cost—not a change in the deal thesis. The 7.625% rate raises the burden of proving that AMS’s growth and planned synergies can outpace the added interest expense.
The deal has a built-in backstop if closing fails. If AMS is not acquired by June 25, 2027, or the cooperation agreement is terminated, Fuller must redeem $450 million of the notes at par plus accrued interest. This limits some transaction-failure risk, but leaves the company carrying a high-coupon obligation while the acquisition remains pending.
Bottom line: The filing advances the AMS transaction from committed financing toward funded execution, but does so at a meaningful interest cost. It is strategically supportive, not an unambiguously positive capital-market event.
AMS acquisition closing before June 25, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!